Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. SK3 Group Inc. (SKTO) Message Board

"Tennessee families with seriously ill children a

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36729
Posted On: 01/24/2014 11:07:12 AM
Posted By: bellsandwhistles
"Tennessee families with seriously ill children are fleeing the state for Colorado"

(When Big Pharma owns a state. Senator Lamarr Alexander from Tennessee, high ranking and powerful, was the fourth highest recipient of Big Pharma campaign "contributions" in 2013-2014. Tennesseans take second billing as the most over-medicated people in the US. More prescriptions per capita are written in Tennessee than in 48 states. According to Pro Publica's "Dollars for Docs," Big Pharma owns influential Tennessean medical professionals, paying them millions of dollars to salute and advocate the newest Big Pharma drugs to their fellow professionals and professional associations. In 2009, key Tennessee doctors received about $8mil for Big Pharma advocacy. In 2012 , doctors nationwide received $2 billion in direct payments and gratuities from 15 big drugmakers.)

Medical Marijuana And The Need To Leave Tennessee

by Abby White
Jan 23, 2014


Tennessee families with seriously ill children are fleeing the state for Colorado, where they'll have access to medical marijuana. The Mattison family left Nashville last week, and are settling into Colorado Springs with their three children, Neal (10), Sam (7) and Millie (22 months). Millie has been suffering infantile spasms since she was three months old and is already taking an adult dosage of her current medication. When her doctors wanted to increase the dosage further — with little hope for improvement — the Mattisons started researching medical marijuana.

Why?


Part of the answer, from today's Scene piece:


Millie sees a neurologist at the Neurometabolic Clinic at the Cincinnati Children's Hospital every three months. Between visits to Cincinnati, Millie frequents the emergency room at Vanderbilt. But the cause of her seizures is still unknown.

She's endured intubations, blood transfusions, spinal taps, MRIs, CAT scans, genetic testing and stints in the pediatric intensive care unit, one due to kidney shutdown from an anti-seizure ketogenic diet. She's been on as many as 11 medications at one time and relies upon a feeding tube. Her current medication, Sabril, leaves her lethargic and has severe potential side effects, including blindness.


"One study we looked at said that if two anti-epileptics don't work, there's a 10 percent chance that any of them will work," Penn says. "If four don't work, there's a 0.8 percent chance. We've been on six. Nothing has really helped that much. She sleeps 20, 22 hours a day — there's no way she can build any muscle tone or development skills.



Although HB 1385, also known as the Koozer-Kuhn Medical Cannabis Act, was presented by state Rep. Sherry Jones (D-Nashville) on 07 January, it stands little chance of passing. (courtesy of Big Pharma)


Paul Kuhn, whose wife Jeanne found relief in medical marijuana before she passed away from cancer in 1996, is the former national chairman of the lobbying group National Organization for the Reform of Marijuana Laws. Despite the current political climate and opposition to the bill, Kuhn, who continues to serve on NORML's board, is optimistic about HB 1385.


"It will pass," Kuhn states, with a confidence many sympathetic voters don't share. "We're very close to the tipping point. There will be, this year, probably five to eight additional states that pass. So do we want Tennessee to be holding up the rear? It doesn't do our state image any good to be the laggers in a very progressive movement."


On Monday, January 27, a symposium "Koozer-Kuhn: Re-establishing a Medical Cannabis Program in Tennessee" will be held at Vanderbilt Owen School of Management from 7-8:30 pm, featuring speeches from legislators and patients. This is an 80-seat hall and audio will be broadcast in adjacent rooms to handle overflow.




Big Pharma


(0)
(0)




SK3 Group Inc. (SKTO) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us